Patents by Inventor Kelley E Smith

Kelley E Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200385752
    Abstract: The subject invention relates to a novel gene referred to herein as DSM-2. This gene was identified in Streptomyces coelicolor A3. The DSM-2 protein is distantly related to PAT and BAR. The subject invention also provides plant-optimized genes encoding DSM-2 proteins. DSM-2 can be used as a transgenic trait to impart tolerance in plants and plant cells to the herbicides glufosinate and bialaphos. One preferred use of the subject genes areas selectable markers. The use of this gene as a selectable marker in a bacterial system can increase efficiency for plant transformations. Use of DSM-2 as the sole selection marker eliminates the need for an additional medicinal antibiotic marker (such as ampicillin resistance) during cloning. Various other uses are also possible according to the subject invention.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 10, 2020
    Applicant: Dow AgroSciences LLC
    Inventors: Justin M Lira, Terry Wright, Andrew E. Robinson, Sean Russell, Donald J Merlo, Steven Webb, Nicole L Arnold, Kelley E Smith
  • Publication number: 20200385751
    Abstract: The subject invention relates to a novel gene referred to herein as DSM-2. This gene was identified in Streptomyces coelicolor A3. The DSM-2 protein is distantly related to PAT and BAR. The subject invention also provides plant-optimized genes encoding DSM-2 proteins. DSM-2 can be used as a transgenic trait to impart tolerance in plants and plant cells to the herbicides glufosinate and bialaphos. One preferred use of the subject genes are as selectable markers. The use of this gene as a selectable marker in a bacterial system can increase efficiency for plant transformations. Use of DSM-2 as the sole selection marker eliminates the need for an additional medicinal antibiotic marker (such as ampicillin resistance) during cloning. Various other uses are also possible according to the subject invention.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 10, 2020
    Applicant: Dow AgroSciences LLC
    Inventors: Justin M Lira, Terry Wright, Andrew E. Robinson, Sean Russell, Donald J Merlo, Steven Webb, Nicole L Arnold, Kelley E Smith